adenosin
nucleosid
analog
directact
antivir
drug
investig
treatment
seriou
lifethreaten
infect
highli
pathogen
virus
ebola
viru
cellular
kinas
phosphoryl
triphosph
mimic
atp
viral
rna
polymeras
incorpor
drug
monophosph
nucleotid
grow
rna
chain
caus
prematur
chain
termin
activ
vitro
mani
rna
viral
pathogen
includ
filovirus
emerg
infecti
agent
merscov
sarscov
vivo
activ
intramuscular
intraperiton
oral
administr
varieti
experiment
infect
nonclin
studi
involv
lethal
infect
ebola
viru
marburg
viru
rift
valley
fever
viru
yellow
fever
viru
demonstr
pronounc
efficaci
experi
conduct
sever
model
reduct
viral
load
improv
surviv
found
relat
dose
phase
clinic
trial
intramuscular
administr
healthi
subject
current
ongo
adenosin
nucleosid
analog
directact
antivir
drug
investig
treatment
seriou
lifethreaten
infect
highli
pathogen
virus
ebola
viru
cellular
kinas
phosphoryl
triphosph
mimic
atp
viral
rna
polymeras
incorpor
drug
monophosph
nucleotid
grow
rna
chain
caus
prematur
chain
termin
activ
vitro
mani
rna
viral
pathogen
includ
filovirus
emerg
infecti
agent
merscov
sarscov
vivo
activ
intramuscular
intraperiton
oral
administr
varieti
experiment
infect
nonclin
studi
involv
lethal
infect
ebola
viru
marburg
viru
rift
valley
fever
viru
yellow
fever
viru
demonstr
pronounc
efficaci
experi
conduct
sever
model
reduct
viral
load
improv
surviv
found
relat
dose
phase
clinic
trial
intramuscular
administr
healthi
subject
current
ongo
king
saud
bin
abdulaziz
univers
health
scienc
right
reserv
nucleosid
analog
drug
highli
success
treatment
rang
seriou
lifethreaten
viral
infect
nucleosid
analog
target
fundament
reproduct
mechan
viral
genom
exampl
acyclovir
introduc
treat
herpesviru
enceph
target
dna
polymeras
zidovudin
introduc
treat
infect
human
immunodefici
viru
target
revers
transcriptas
sofosbuvir
recent
approv
treatment
hepat
c
target
rna
polymeras
viralencod
rna
polymeras
essenti
replic
rna
virus
host
cell
catalyz
synthesi
multipl
copi
complementari
rna
templat
viral
rna
basepair
nucleotid
incorpor
specif
bind
triphosph
nucleotid
enzym
rna
templat
follow
cleavag
pyrophosph
coval
bond
nucleotid
posit
grow
rna
strand
therefor
desir
characterist
antivir
nucleosid
includ
effici
uptak
cell
effici
convers
nucleosid
triphosph
nucleotid
mammalian
kinas
fresh
hepatocyt
mice
rat
nonhuman
primat
human
vitro
fig
left
panel
im
inject
rat
vivo
fig
right
panel
effici
taken
cell
convert
triphosph
tp
vivo
convers
tp
nucleotid
particularli
effici
exampl
intracellular
level
higher
plasma
level
parent
compound
within
min
intramuscular
administr
continu
exceed
plasma
drug
level
least
h
singl
dose
molecular
goal
antivir
therapi
rna
polymeras
inhibitor
interrupt
viral
rna
synthesi
desir
characterist
candid
nucleosid
drug
structur
mimicri
correspond
natur
nucleotid
mimicri
allow
drug
nucleotid
triphosph
recogn
viral
rna
polymeras
substitut
correspond
natur
nucleotid
artifici
nucleotid
similar
either
natur
purin
adenosin
guanosin
natur
pyrimidin
uracil
cytosin
nucleosid
may
structur
modif
either
base
ribos
sugar
moieti
fig
adenosin
analog
substitut
carbon
nitrogen
posit
base
nitrogen
oxygen
posit
ribos
ring
steric
electrostat
interact
substitut
ribos
ring
known
alter
conform
sugar
conform
chang
turn
affect
nucleotid
incorpor
chain
extens
polymeras
structur
chang
furanos
adenosin
azasugar
ring
alter
electrostat
interact
ring
viral
rnadepend
rna
polymeras
unabl
add
one
two
nucleotid
demonstr
vitro
use
hepat
c
rna
polymeras
assay
fig
studi
hadenosin
human
hepatocellular
carcinoma
cell
line
incap
incorpor
label
either
rna
dna
despit
avid
incorpor
label
natur
nucleosid
specif
inhibitori
activ
like
antivir
nucleosid
drug
viral
rna
polymeras
compar
mammalian
rna
dna
polymeras
possibl
due
superior
errorcorrect
capabl
mammalian
enzym
howev
factor
exclud
viru
prolifer
cell
cultur
inhibit
incub
display
broad
spectrum
activ
wide
varieti
rna
viral
pathogen
mani
virus
includ
merscov
ebov
marv
yfv
caus
seriou
cell
incub
indic
time
level
quantit
hplc
plasma
sampl
obtain
liver
harvest
rat
follow
administr
mgkg
dose
intramuscular
inject
plasma
liver
quantit
hplctandem
ms
fatal
infect
current
either
approv
treatment
treatment
limit
efficaci
antivir
activ
demonstr
virus
divers
taxa
includ
positivesens
flavivirida
coronavirida
rna
virus
negativesens
filovirida
arenavirida
bunyavirida
orthomyxovirida
picornavirida
paramyxovirida
rna
virus
antivir
activ
filovirus
also
evalu
hela
cell
line
assay
quantit
intracellular
viral
rna
marv
ebov
extracellular
rna
ebov
supernat
report
vitro
ec
valu
vari
across
wide
rang
howev
mani
cell
line
use
antivir
drug
sensit
assay
ineffici
anabol
fig
exampl
result
suscept
assay
ineffici
cell
line
vero
jordan
strain
merscov
strain
yellow
fever
viru
shown
fig
ec
estim
doubledigit
micromolar
rang
appar
observ
high
ec
valu
may
mislead
vivo
studi
requir
investig
antivir
activ
compound
experiment
diseas
model
lethal
viru
infect
rodent
nonhuman
primat
help
understand
potenti
util
candid
antivir
drug
date
shown
efficaci
lethal
rodent
nhp
model
filovir
diseas
marburg
viru
diseas
mvd
ebola
viru
diseas
evd
well
rodent
model
yellow
fever
rift
valley
fever
studi
cynomolgu
macaqu
infect
marv
control
surviv
compar
anim
treat
mgkg
bd
dose
maximum
viral
load
measur
quantit
viral
rna
copi
peripher
blood
reduc
geometr
mean
compar
copiesml
p
diseas
marker
elev
bilirubin
ast
hepat
prolong
aptt
pt
coagulopathi
also
markedli
improv
p
doserang
studi
cynomolgu
macaqu
evd
model
evalu
dose
rang
mgkg
bid
im
start
h
inocul
anim
surviv
howev
mgkg
bid
dose
group
mean
time
death
significantli
prolong
compar
control
group
vs
p
geometr
mean
viral
rna
copiesml
serum
significantli
reduc
day
vs
redrawn
copiesml
control
differ
log
p
subsequ
studi
rhesu
macaqu
evd
model
six
anim
administ
dose
mgkg
im
bid
start
min
inocul
surviv
compar
zero
six
control
p
viral
load
reduc
log
group
day
geometr
mean
viral
rna
copiesml
serum
vs
control
p
show
potent
vivo
antivir
activ
studi
use
yellow
fever
model
syrian
golden
hamster
administr
dose
mgkg
qd
highli
effect
reduc
mortal
even
initi
treatment
delay
much
day
inocul
import
note
vitro
suscept
test
yfv
shown
doubledigit
micromolar
ec
fig
right
panel
emphas
would
unwis
reject
util
particular
viru
base
sole
vitro
suscept
test
slope
relationship
dose
antivir
effect
surviv
nonclin
model
lethal
viral
infect
steep
exampl
shown
experiment
yellow
fever
hamster
fig
estim
hill
slope
log
antivir
effect
ed
dose
estim
mgkg
bid
r
fig
left
panel
ed
dose
surviv
estim
mgkg
bid
logist
regress
best
fit
experiment
data
p
r
doubl
dose
mgkg
bid
mgkg
bid
increas
odd
surviv
approxim
doserespons
surviv
also
steep
mous
model
marburg
viru
diseas
phase
firstinhuman
studi
intramuscular
inject
healthi
subject
ongo
singl
dose
mgkg
plasma
exposur
doserel
linear
first
multiday
cohort
evalu
dose
mgkg
qd
day
dose
escal
continu
date
inject
safe
well
toler
addit
studi
healthi
subject
plan
use
intraven
rout
administr
mechan
action
vitro
antivir
activ
nonclin
efficaci
discuss
repres
highli
attract
profil
broadspectrum
antivir
agent
bodi
evid
attract
fund
continu
develop
us
govern
agenc
program
support
part
us
feder
contract
nihniaid
hhsbarda
program
advanc
earli
clinic
develop
togeth
latestag
nonclin
toxicolog
drug
suppli
scaleup
activ
drug
substanc
crystallin
solid
proven
stabl
ongo
studi
least
year
tradit
small
molecul
chemic
entiti
develop
drug
substanc
synthet
process
formul
drug
product
pursu
use
standard
chemistri
manufactur
formul
research
practic
expect
largescal
synthesi
highqual
finish
product
achiev
pharmacokinet
profil
nonclin
speci
support
evalu
daili
dose
efficaci
demonstr
experiment
viral
infect
model
parenter
im
ip
oral
rout
administr
gener
safe
well
toler
ongo
healthi
human
subject
safeti
studi
clinic
pharmacolog
profil
emerg
studi
help
refin
optim
therapeut
dose
schedul
complet
develop
anim
rule
use
clinic
test
relev
diseas
set
recent
disastr
outbreak
ebola
viru
diseas
west
african
nation
emerg
merscov
infect
middl
east
underscor
import
urgenc
success
develop
effect
safe
antivir
drug
treatment
lifethreaten
ill
addit
continu
drug
synthesi
formul
research
enabl
largescal
drug
suppli
contract
contract
inventori
import
categori
research
complet
near
term
field
nonclin
pharmacolog
nonclin
diseas
model
clinic
pharmacolog
doserespons
studi
nonclin
infect
model
nonclin
pharmacolog
studi
plasma
tissu
pharmacokinet
healthi
experiment
infect
anim
optim
doseschedul
studi
nonclin
diseas
model
delay
dose
studi
nonclin
diseas
model
complet
phase
studi
healthi
subject
defin
maximum
toler
dose
explor
exposur
via
im
iv
rout
administr
complet
nonclin
safeti
studi
support
emerg
usag
readi
evalu
evalu
relationship
dose
plasma
drug
exposur
virolog
respons
patient
relev
viral
infect
opportun
evid
research
program
would
provid
sound
basi
select
dose
regimen
use
emerg
respons
set
work
describ
fund
whole
part
feder
fund
nation
institut
allergi
infecti
diseas
nation
institut
health
depart
health
human
servic
contract
rt
sd
ar
yek
yb
wp
employe
andor
stockhold
biocryst
pharmaceut
inc
requir
